Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV

Next Previous
Trial Profile

An Open-Label Phase 3b Study to Assess Mucosal Healing in Subjects With Moderately to Severely Active Crohn's Disease Treated With Vedolizumab IV

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vedolizumab (Primary)
  • Indications Crohn's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms VERSIFY
  • Sponsors Takeda

Most Recent Events

  • 01 Jul 2022 Results of pooled analysis from NCT01369329, NCT02425111, NCT02096861 and other study comparing the efficacy of adalimumab, infliximab, ustekinumab, and vedolizumab on the ability to achieve endoscopic healing (EH) after 1 year of therapy in moderate-severe Crohns disease, published in the American Journal of Gastroenterology
  • 17 May 2022 Results (n=69) assessing a computational approach integrating a mechanistic model of Crohn's disease with a responder classifier to predict temporal changes in mucosal health published in the Advances in Therapy
  • 19 May 2020 Results published in Gasteroenterology in conjunction with Digestive Disease Week 2020

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top